Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock (Launch)

Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS

Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting

Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering

Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference

Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia